Listed biotech firm Selvita wants to earmark the over PLN 134 million expected from its pending SPO for innovative projects in the field of oncology and for a molecular tools platform as well as expansion of its services offer and laboratory infrastructure, CEO Pawel Przewiezlikowski tells the daily Parkiet.
PLN 70 million worth of part of SPO receipts will go for financing the SEL120 project, which the firm wants to take to the second stage of clinical research this year, CEO adds. In 2018, Selvita wants to delegate operational responsibility for the SEL24 project to its Italian partner Menarini, Przewiezlikowski reveals. Selvita is too small a firm to venture a debut on a foreign market, CEO says. The company might, however, start to think about courting foreign investors once its capitalization hits several hundred million dollars and when the therapeutic potential of its molecules is confirmed, Przewiezlikowski adds.